| Literature DB >> 35203551 |
Patrick Lau1, Laurence Vico2, Jörn Rittweger1,3.
Abstract
The dissociation of bone formation and resorption is an important physiological process during spaceflight. It also occurs during local skeletal unloading or immobilization, such as in people with neuromuscular disorders or those who are on bed rest. Under these conditions, the physiological systems of the human body are perturbed down to the cellular level. Through the absence of mechanical stimuli, the musculoskeletal system and, predominantly, the postural skeletal muscles are largely affected. Despite in-flight exercise countermeasures, muscle wasting and bone loss occur, which are associated with spaceflight duration. Nevertheless, countermeasures can be effective, especially by preventing muscle wasting to rescue both postural and dynamic as well as muscle performance. Thus far, it is largely unknown how changes in bone microarchitecture evolve over the long term in the absence of a gravity vector and whether bone loss incurred in space or following the return to the Earth fully recovers or partly persists. In this review, we highlight the different mechanisms and factors that regulate the humoral crosstalk between the muscle and the bone. Further we focus on the interplay between currently known myokines and osteokines and their mutual regulation.Entities:
Keywords: bone formation; bone remodeling; bone resorption; disuse; space medicine; unloading
Year: 2022 PMID: 35203551 PMCID: PMC8961781 DOI: 10.3390/biomedicines10020342
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Schematic illustration of the most important spaceflight health issues experienced by space travelers. The microgravity environment exerts a multitude of human health hazards (e.g., psychological effects, exposure to space radiation, immune deficiency and microgravity). Focusing on the musculoskeletal system, weightlessness conditions promote muscle atrophy as well as bone loss (I). Considering their spatially distance, it is most likely, that muscle and bone are metabolically interconnected and highly vascularized (II). Osteocytes sense external mechanical signals and transduce them into internal biochemical signals. Therefore, they are realized as the principal regulators of bone mechanosensation and mechanotransduction. Mechanical loading or unloading increases the osteocyte membrane tension which further induces the opening of PIEZO1 channels. Specifically, mechanically activated nonselective Ca2+-permeable cation channels of the PIEZO family (PIEZO1 and PIEZO2) are recognized as the most important mediators of mechanotransduction. SOST, a protein secreted by osteocytes is a member of the Dickkopf family, and also a potent suppressor of canonical Wnt-β-catenin signaling pathway via Lrp5/6, negatively regulates bone formation. Under weightlessness conditions, upregulation of TGF-β1 as well as RANKL has been considered as an important indicator of osteoclast activation and differentiation (III). Myokines and osteokines are released by skeletal muscle and bone tissue into the blood circulation. Microgravity therefore triggers the dissociation of bone formation and resorption (IV).
Figure 2Myokines and osteokines produced and secreted by the skeletal muscle tissues and the bone tissues. Myokines like Irisin, IGF-1and L-BAIBA, LIF and BMP-7 positively alter the bone tissue by upregulating the activity of osteoblasts. In parallel myokines like myostatin, IL-6, IL-7 and FGF-23 stimulate bone resorption and therefore negatively regulate bone mass. Conversely, several bone cell-derived factors circulating in the periphery named osteokines influence local and systemic metabolism. They directly stimulate myogenesis and affect muscle function. Osteokines such as ucOCN, derived from bone affect skeletal muscle positively, which in turn improves muscle functions during exercise. Others such as SOST, DKK1 and RANKL effect the muscle function negatively which in turn reduces muscle function and strength.
Selected myokines with proven functions in humans and their effects on bone.
| Marker | Abb. | Action | Ref. |
|---|---|---|---|
| Brain-derived neurotrophic factor | BDNF | Regulates VEGF secretion by osteoblasts. | [ |
| Bone matrix decorin | DCN | Binds to TGFβ and enhances its inhibitory effect on the proliferation of osteoblastic cells, is regulated by exercise, and acts as an antagonist to myostatin. | [ |
| Bone morphogenic protein 7 | BMP-7 | Important factor in bone formation and skeletal muscle mass maintenance. Induces osteoblastic cell differentiation of C2C12 cells. | [ |
| Fibroblast growth factor 2 | FGF-2 | Localized to muscle–bone interface in vivo, SOST signaling inhibitor. | [ |
| Fibroblast growth factor 21 | FGF-21 | Mediator of glucose uptake in skeletal muscle, leads to bone resorption. | [ |
| Follistatin-like 1 | Fsl-1 | Negative regulator of muscle growth. | [ |
| Growth differentiation factor 15 | GDF-15 | Secreted from skeletal muscle in response to mitochondrial stress. | [ |
| Insulin-like growth factor 1 | IGF-1 | Secreted from cultured myotubes in vitro, stimulates bone formation both in vitro and in vivo. Receptors are abundantly localized to the periosteum at the muscle–bone interface. | [ |
| Insulin-like growth factor-1Ea | IGF-1Ea | Expression of the full propeptide protects against age-related loss of muscle mass and strength. | [ |
| Interleukin 15 | IL-15 | Supports osteoblastic matrix formation, potent proliferator of innate immune cells. | [ |
| Interleukin 6 | IL-6 | Increases osteoclast activity, proinflammatory. | [ |
| Interleukin 7 | IL-7 | Promotes osteoclastogenesis and inflammatory responses and inhibits bone formation. | [ |
| Interleukin 8 | IL-8 | Positive effects on muscular angiogenesis. | [ |
| Irisin (fibronectin type III domain containing 5) | FNDC5 | Anabolic effect on bone, improves osteoblastogenesis, improves bone mass in animal models. | [ |
| β-aminoisobutyric acid | L-BAIBA | Prevents osteocyte cell death, preserves bone and muscle, blood levels increase in response to constant exercise, and regulates bone and skeletal muscle loss due to aging. | [ |
| Leukemia inhibitory factor | LIF | Stimulates bone formation in vivo. | [ |
| Matrix metallopeptidase 2 | MMP-2 | Involved in bone formation and metabolism. | [ |
| Musclin/Osteocrin | OSTN | Exercise-induced myokine and is produced by osteoblasts. Specific ligand for natriuretic peptide clearance receptor which modulates bone growth. | [ |
| Myostatin (growth/differentiation factor-8) | GDF-8 | Negative regulator of muscle mass and inhibits osteoblastic differentiation. Exercise reduces its secretion. Promotes osteoclastogenesis induced by RANKL in vitro. | [ |
| Osteoglycin | OGN | Inhibits myoblast migration during myogenesis. | [ |
| Osteonectin (secreted protein, acidic, rich in cysteine) | SPARC | Elevated levels in muscle and plasma of mice and humans post-exercise. Exercise reported to induce osteonectin secretion from the muscle tissue. | [ |
| Transforming growth factor beta 1 | TGF-β1 | Stimulates matrix protein production by osteoblasts. | [ |
Selected osteokines with proven functions in humans and their effects on muscle.
| Marker | Abb. | Action | Ref. |
|---|---|---|---|
| Undercarboxylated osteocalcin | ucOCN | Positive effects on the muscle mass and associated functions. Vital for adaptation to exercise. Insulin-dependent increase in glucose uptake in mice. | [ |
| Dickkopf 1 | DKK1 | Catabolic osteokine that downregulates bone formation through the inhibition of the Wnt pathway. Expressed by osteocytes and osteoblasts. | [ |
| Sclerostin | SOST | Suppresses Wnt3a-mediated crosstalk between MLO-Y4 osteocytes and muscle cells C2C12 by regulating the Wnt/β-catenin pathway. Inhibition restores muscle function in cancer-induced muscle weakness. Muscle-derived SOST works synergistically with bone-derived SOST to strengthen the negative regulatory mechanisms of osteogenesis. | [ |
| Insulin-like growth factor 1 | IGF-1 | Bone formation stimulation found in vitro and in vivo. Important myokine for bone. | [ |
| Fibroblast growth factor 9 | FGF-9 | Expressed in bone. FGF-9 mRNA expression is highly enriched in osteocytes. | [ |
| Fibroblast growth factor 23 | FGF-23 | Mainly produced in osteocytes. Crucial regulator of phosphate and calcium metabolism via multiple organs. | [ |
| Osteoprotegerin | OPG | Main regulator for osteoclast differentiation and also the bone remodeling. Novel protector of muscle integrity. | [ |
| Receptor activator of NF-κB ligand | RANKL | Inhibits muscle mass and function. | [ |
| Wnt family member 3a | Wnt3a | Wnt3a accelerates C2C12 differentiation. | [ |
| Prostaglandin E2 | PGE2 | Mimics specific effects of the osteocyte-secreted factors on the process of myogenesis and also the muscle function. | [ |
| Fibroblast growth factor 2 | FGF-2 | Involved in normal skeletal growth. | [ |
| Lipocalin-2 | LCN-2 | Mechanoresponding gene, which may correlate with poor osteoblast activity | [ |